A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 50, Issue 1, 2006, Pages 61-67

  Santiago, J F Y ^a   Gonen, M ^b   Yeung, H ^b   Macapinlac, H ^c   Larson, S ^b  

^a ST LUKE S MEDICAL CENTER   (Philippines)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast neoplasms, radionuclide imaging Fluodeoxyglucode, F18; Tomography, emission computed

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 33646180825     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cancer Research Campaign. Breast Cancer. UK, fact sheet 1996.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
3. Duffy SW, Chen HH, Tabar L, Fagerberg G, Paci E. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49. Int J Epidemiol 1996;25:1139-45.
4. Rubens RD. The management of locally advanced breast cancer. Br J Cancer 1992;65:145-7.
5. Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER. Relation of the number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 1983;52:1551-7.
6. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807-14.
7. Ciatto S. Detection of breast cancer local recurrences. Ann Oncol 1995;6 Suppl 2:23-6.
8. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989;13:1097-8.
9. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002;23:613-8.
10. Yasuda S, Shohtsu A. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet 1997;350: 1819.
11. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-5.
12. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687-92.
13. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998;228:220-7.
14. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
15. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
16. Tunis S, Phurrough S, Burken M, Stojak M, Caplan S. FDG positron emission tomography (PET)-breast cancer CAG-00094A: a decision memorandum. February 27, 2002.
17. Tunis S, Stojak M, Richardson S, Burken M, Londner M, Ulrich M et al. FDG PET CAG-00065: a decision memorandum. December 15,2000.
18. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375-9.
19. 99mTc-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9.
20. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002;9:913-21.
21. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8.
22. 18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129:147-53.
23. 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001;42:1334-7.
24. Adler LP, Crowe JP, Al-kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with FDG PET. Radiology 1993;187:743-50.
25. Adler LP, Faulhaber PF, Schnur KC, Al-Kaisi NL, Schenk RR. Axillary lymph node metastases: screening with FDG PET. Radiology 1997;203:323-7.
26. Utech CI, Young CS, Winter PF. Prospective evaluation of FDG PET in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588-93.
27. 18F-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4-8.
28. 18-FDG whole body positron emission tomography in primary breast sarcoma. Clin Nucl Med 1998;9:604-8.
29. Avril N, Dose J, Janicke F, Bense S, Ziegler S, Laubenbacher C et al. Metabolic characterization of breast tumors with positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. J Clin Oncol 1996;14:1848-57.
30. Crowe JP, Adler LP, Shenk RR, Sunshine J. PET and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-40.
31. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998;28:290-302.
32. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82:2227-34.